Ascendis ready for new hires after FDA approval

For a long time, Ascendis has been preparing for the approval of growth hormone Skytrofa, and the company can now execute launch and expansion plans.

Photo: Kevin Grønnemann/MedWatch

Ascendis Pharma is chomping at the bit after securing a long-awaited approval for Transcon hGH, which will be marketed as Skytrofa. The company has already prepared launch plans to be initiated immediately.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs